Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has initiated Mobility, a clinical trial studying the safety and efficacy of the Absolute Pro peripheral self-expanding stent system in patients with iliac artery disease.
Subscribe to our email newsletter
The Mobility trial is designed to study 150 patients at up to 50 centers in the US. The primary endpoint is a composite measure of major adverse events (MAE) at nine months. MAE is defined as death due to any cause, heart attack, clinically driven target lesion revascularization and limb loss on the treated side.
Charles Simonton, chief medical officer of Abbott Vascular, said: “With iliac interventions, safety and efficacy are critical when considering treatment options. The Mobility trial will provide valuable evidence about the performance of the Absolute Pro peripheral stent, and it will be used as the basis for a peripheral vascular indication filing for the device.”